Inhibitory and bactericidal activities of daptomycin, vancomycin, and teicoplanin against methicillin-resistant Staphylococcus aureus isolates collected from 1985 to 2007

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 5, 2009, Pages 1735-1738

  Traczewski, Maria M ^a   Katz, Bradley D ^b   Steenbergen, Judith N ^b   Brown, Steven D ^a  

^a CLINICAL MICROBIOLOGY INSTITUTE   (United States)

^b CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; TEICOPLANIN; VANCOMYCIN;

ABSCESS CULTURE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTERIUM CULTURE; BACTERIUM ISOLATE; BLOOD CULTURE; DRUG CONCENTRATION; DRUG POTENCY; DRUG TOLERANCE; EUROPE; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; UNITED STATES;

ABSCESS; ANTI-BACTERIAL AGENTS; BLOOD; CULTURE MEDIA; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; TEICOPLANIN; VANCOMYCIN;

EID: 66149128805     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01022-08     Document Type: Article

References (28)

1. Reference deleted.
2. Biedenbach, D. J., J. M. Bell, H. S. Sader, T. R. Fritsche, R. N. Jones, and J. D. Turnidge. 2007. Antimicrobial susceptibility of gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin and teicoplanin: a SENTRY program report (2003-2004). Int. J. Antimicrob. Agents 30: 143-149.
3. Bourgeois, I., M. Pestel-Caron, J.-F. Lemeland, J.-L. Pons, and F. Caron. 2007. Tolerance to the glycopeptides vancomycin and teicoplanin in coagulase-negative staphylococci. Antimicrob. Agents Chemother. 51:740-743. (Pubitemid 46185298)
4. Clinical and Laboratory Standards Institute. 1999. Methods for determining bactericidal activity of antimicrobial agents; approved guideline. Document M26-A. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard. Document M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing: 18th information supplement. Document M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Denny, A. E., L. R. Peterson, D. N. Gerding, and W. H. Hall. 1979. Serious staphylococcal infections with strains tolerant to bactericidal antibiotics. Arch. Intern. Med. 139:1026-1031. (Pubitemid 10115902)
8. Drake, T. A., and M. A. Sande. 1983. Studies of the chemotherapy of endocarditis: correlation of in vitro, animal model, and clinical studies. Rev. Infect. Dis. 5:S345-S354.
9. French, G. L. 2006. Bactericidal agents in the treatment of MRSA infections - the potential role of daptomycin. J. Antimicrob. Chemother. 58:1107-1117.
10. Fuchs, P. C., A. L. Barry, and S. D. Brown. 2002. In vitro bactericidal activity of daptomycin against staphylococci. J. Antimicrob. Chemother. 49:467-470.
11. Hacek, D. M., D. C. Dressel, and L. R. Peterson. 1999. Highly reproducible bactericidal activity test results by using a modified National Committee for Clinical Laboratory Standards broth macrodilution technique. J. Clin. Microbiol. 37:1881-1884. (Pubitemid 29235240)
12. Holmes, R. L., and J. H. Jorgensen. 2008. Inhibitory activities of 11 antimicrobial agents and bactericidal activities of vancomycin and daptomycin against invasive methicillin-resistant Staphylococcus aureus isolates obtained from 1999 to 2006. Antimicrob. Agents Chemother. 52:757-760.
13. Jones, R. N. 2006. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin. Infect. Dis. 42(Suppl. 1):S13-S24.
14. LaPlante, K. L., and M. J. Rybak. 2004. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 48:4665-4672.
15. May, J., K. Shannon, A. King, and G. French. 1998. Glycopeptide tolerance in Staphylococcus aureus. J. Antimicrob. Chemother. 42:189-197.
16. Moise, P. A., G. Sakoulas, A. Forrest, and J. J. Schentag. 2007. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 51:2582-2586.
17. Pankey, G. A., and L. D. Sabath. 2004. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of gram-positive bacterial infections. Clin. Infect. Dis. 38:864-870. (Pubitemid 38387236)
18. Perry, J. D., A. L. Jones, and F. K. Gould. 1999. Glycopeptide tolerance in bacteria causing endocarditis. J. Antimicrob. Chemother. 44:121-124. (Pubitemid 29353692)
19. Peterson, L. R., and C. J. Shanholtzer. 1992. Tests for bactericidal effects of antimicrobial agents: technical performance and clinical relevance. Clin. Microbiol. Rev. 5:420-432.
20. Rodriguez, C. A., R. Atkinson, W. Bitar, C. G. Whitney, K. M. Edwards, L. Mitchell, J. Li, J. Sublett, C. S. Li, T. Lin, P. J. Chesney, and E. I. Tuomanen. 2004. Tolerance to vancomycin in pneumococci: detection with a molecular marker and assessment of clinical impact. J. Infect. Dis. 190:1481-1487. (Pubitemid 39332189)
21. Sader, H. S., T. R. Fritsche, and R. N. Jones. 2006. Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin. Antimicrob. Agents Chemother. 50:2330-2336.
22. Safdar, A. K., and V. I. Rolston. 2006. Vancomycin tolerance, a potential mechanism for refractory gram-positive bacteremia observational study in patients with cancer. Cancer 106:1815-1820.
23. Sakoulas, G., P. A. Moise-Broder, J. Schentag, A. Forrest, R. C. Moellering, Jr., and G. M. Eliopoulos. 2004. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42:2398-2402.
24. Sherris, J. C. 1986. Problems in in vitro determination of antibiotic tolerance in clinical isolates. Antimicrob. Agents Chemother. 30:633-637. (Pubitemid 17187684)
25. Small, P. M., and H. F. Chambers. 1990. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob. Agents Chemother. 34:1227-1231.
26. Vaudaux, P., P. Francois, C. Bisognano, D. Li, D. P. Lew, and J. Schrenezel. 2003. Comparative efficacy of daptomycin and vancomycin in the therapy of experimental foreign body infection due to Staphylococcus aureus. J. Antimicrob. Chemother. 52:89-95. (Pubitemid 36850091)
27. Voorn, G. P., J. Kuyvenhoven, W. H. F. Goessens, W. C. Schmal-Bauer, P. H. M. Broeders, J. Thompson, and M. F. Michel. 1994. Role of tolerance in treatment and prophylaxis of experimental Staphylococcus aureus endocarditis with vancomycin, teicoplanin, and daptomycin. Antimicrob. Agents Chemother. 38:487-493.
28. Wootton, M., A. P. Macgowan, and T. R. Walsh. 2006. Comparative bactericidal activities of daptomycin and vancomycin against glycopeptide-intermediate Staphylococcus aureus (GISA) and heterogeneous GISA isolates. Antimicrob. Agents Chemother. 50:4195-4197.